Cemiplimab

CAS 1785585-98-6 2 FDA-DMF suppliersBiologic

Overview

Cemiplimab is a monoclonal antibody that inhibits PD-1 and is used in the treatment of certain types of cancer. It is particularly used for managing advanced cutaneous squamous cell carcinoma.

Therapeutic areas

OncologySkin CancerCutaneous Squamous Cell Carcinoma

Related APIs

Vismodegib
8 suppliers
Paclitaxel
33 suppliers
Anastrozole
28 suppliers
Capecitabine
27 suppliers
Bicalutamide
26 suppliers
Zoledronic Acid
25 suppliers
Dasatinib
24 suppliers
Bortezomib
24 suppliers

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo